These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 14760175)

  • 21. Reactions to infliximab in patients with rheumatoid arthritis.
    Sakellariou GT; Chatzigiannis I
    J Rheumatol; 2005 Jul; 32(7):1411-2. PubMed ID: 15996088
    [No Abstract]   [Full Text] [Related]  

  • 22. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors.
    Segan J; Staples MP; March L; Lassere M; Chakravarty EF; Buchbinder R
    Intern Med J; 2015 Mar; 45(3):310-8. PubMed ID: 25565419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interstitial pneumonitis associated with infliximab therapy.
    Villeneuve E; St-Pierre A; Haraoui B
    J Rheumatol; 2006 Jun; 33(6):1189-93. PubMed ID: 16622902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Occurrence of pulmonary thromboembolism during infliximab therapy.
    Eklund KK; Peltomaa R; Leirisalo-Repo M
    Clin Exp Rheumatol; 2003; 21(5):679. PubMed ID: 14611130
    [No Abstract]   [Full Text] [Related]  

  • 25. Polymyositis associated with infliximab treatment for rheumatoid arthritis.
    Musiał J; Undas A; Celińska-Lowenhoff M
    Rheumatology (Oxford); 2003 Dec; 42(12):1566-8. PubMed ID: 14645861
    [No Abstract]   [Full Text] [Related]  

  • 26. Morbidity and mortality in rheumatoid patients during treatment with adalimumab and infliximab.
    Molloy E; Ramakrishnan S; Murphy E; Barry M
    Rheumatology (Oxford); 2004 Apr; 43(4):522-3. PubMed ID: 15024136
    [No Abstract]   [Full Text] [Related]  

  • 27. Infliximab-associated lymphoproliferative disorders.
    Hoshida Y; Yamamoto S; Wada N; Xu JX; Sasaki T; Aozasa K
    Int J Hematol; 2005 May; 81(4):356-7. PubMed ID: 15914370
    [No Abstract]   [Full Text] [Related]  

  • 28. Ophthalmic herpes zoster infection in patients with rheumatoid arthritis who were treated with tocilizumab.
    Roux C; Breuil V; Albert C; Allam V; Grisot C; Chami H; Dasilva V; Euller-Ziegler L
    J Rheumatol; 2011 Feb; 38(2):399. PubMed ID: 21285184
    [No Abstract]   [Full Text] [Related]  

  • 29. Cyclosporine in addition to infliximab and methotrexate in refractory rheumatoid arthritis.
    Marchesoni A; Sarzi Puttini P; Gorla R; Caporali R; Arnoldi C; Atzeni F; Vianelli M; Pallavicini FB
    Clin Exp Rheumatol; 2005; 23(6):916-7. PubMed ID: 16396721
    [No Abstract]   [Full Text] [Related]  

  • 30. Disseminated Cryptococcus neoformans after treatment with infliximab for rheumatoid arthritis.
    Kozic H; Riggs K; Ringpfeil F; Lee JB
    J Am Acad Dermatol; 2008 May; 58(5 Suppl 1):S95-6. PubMed ID: 18489059
    [No Abstract]   [Full Text] [Related]  

  • 31. Peptostreptococcal pericarditis complicating anti-tumour necrosis factor alpha treatment in rheumatoid arthritis.
    Harney S; O'Shea FD; FitzGerald O
    Ann Rheum Dis; 2002 Jul; 61(7):653-4. PubMed ID: 12079913
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis.
    Favalli EG; Sinigaglia L; Varenna M; Arnoldi C
    Lupus; 2002; 11(11):753-5. PubMed ID: 12475006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reactivation of brucellosis after treatment with infliximab in a patient with rheumatoid arthritis.
    Jiménez FG; Colmenero JD; Irigoyen MV
    J Infect; 2005 May; 50(4):370-1. PubMed ID: 15845443
    [No Abstract]   [Full Text] [Related]  

  • 34. Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab.
    Aouba A; De Bandt M; Aslangul E; Atkhen N; Patri B
    Rheumatology (Oxford); 2003 Jun; 42(6):800-2. PubMed ID: 12771439
    [No Abstract]   [Full Text] [Related]  

  • 35. Infliximab-induced vitiligo.
    Ramírez-Hernández M; Marras C; Martínez-Escribano JA
    Dermatology; 2005; 210(1):79-80. PubMed ID: 15604556
    [No Abstract]   [Full Text] [Related]  

  • 36. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Hochman D; Wolff B
    JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
    [No Abstract]   [Full Text] [Related]  

  • 37. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Callegari PE; Schaible TF; Boscia JA
    JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
    [No Abstract]   [Full Text] [Related]  

  • 38. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Costenbader KH; Glass R; Cui J; Shadick N
    JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
    [No Abstract]   [Full Text] [Related]  

  • 39. Severe interstitial pneumonitis associated with infliximab therapy.
    Chatterjee S
    Scand J Rheumatol; 2004; 33(4):276-7. PubMed ID: 15370726
    [No Abstract]   [Full Text] [Related]  

  • 40. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis.
    Vandevyvere K; Luyten FP; Verschueren P; Lories R; Segaert S; Westhovens R
    Clin Rheumatol; 2007 Dec; 26(12):2205-2206. PubMed ID: 17876646
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.